Fungal Dysbiosis and Intestinal Inflammation in Children With Beta-Cell Autoimmunity

Jarno Honkanen, Arja Vuorela, Daniel Muthas, Laura Orivuori, Kristiina Luopajärvi, Mysore Vishakante Gowda Tejesvi, Anton Lavrinienko, Anna Maria Pirttilä, Christopher L Fogarty, Taina Härkönen, Jorma Ilonen, Terhi Ruohtula, Mikael Knip, Janne J Koskimäki, Outi Vaarala, Jarno Honkanen, Arja Vuorela, Daniel Muthas, Laura Orivuori, Kristiina Luopajärvi, Mysore Vishakante Gowda Tejesvi, Anton Lavrinienko, Anna Maria Pirttilä, Christopher L Fogarty, Taina Härkönen, Jorma Ilonen, Terhi Ruohtula, Mikael Knip, Janne J Koskimäki, Outi Vaarala

Abstract

Although gut bacterial dysbiosis is recognized as a regulator of beta-cell autoimmunity, no data is available on fungal dysbiosis in the children at the risk of type 1 diabetes (T1D). We hypothesized that the co-occurrence of fungal and bacterial dysbiosis contributes to the intestinal inflammation and autoimmune destruction of insulin-producing beta-cells in T1D. Fecal and blood samples were collected from 26 children tested positive for at least one diabetes-associated autoantibody (IAA, GADA, IA-2A or ICA) and matched autoantibody-negative children with HLA-conferred susceptibility to T1D (matched for HLA-DQB1 haplotype, age, gender and early childhood nutrition). Bacterial 16S and fungal ITS2 sequencing, and analyses of the markers of intestinal inflammation, namely fecal human beta-defensin-2 (HBD2), calprotectin and secretory total IgA, were performed. Anti-Saccharomyces cerevisiae antibodies (ASCA) and circulating cytokines, IFNG, IL-17 and IL-22, were studied. After these analyses, the children were followed for development of clinical T1D (median 8 years and 8 months). Nine autoantibody positive children were diagnosed with T1D, whereas none of the autoantibody negative children developed T1D during the follow-up. Fungal dysbiosis, characterized by high abundance of fecal Saccharomyces and Candida, was found in the progressors, i.e., children with beta-cell autoimmunity who during the follow-up progressed to clinical T1D. These children showed also bacterial dysbiosis, i.e., increased Bacteroidales and Clostridiales ratio, which was, however, found also in the non-progressors, and is thus a common nominator in the children with beta-cell autoimmunity. Furthermore, the progressors showed markers of intestinal inflammation detected as increased levels of fecal HBD2 and ASCA IgG to fungal antigens. We conclude that the fungal and bacterial dysbiosis, and intestinal inflammation are associated with the development of T1D in children with beta-cell autoimmunity.

Keywords: Candida; Saccharomyces; dysbiosis; gut; inflammation; mycobiome; type 1 diabetes.

Copyright © 2020 Honkanen, Vuorela, Muthas, Orivuori, Luopajärvi, Tejesvi, Lavrinienko, Pirttilä, Fogarty, Härkönen, Ilonen, Ruohtula, Knip, Koskimäki and Vaarala.

Figures

Figure 1
Figure 1
Study design: Microbiome composition, intestinal inflammation and the development of clinical type 1 diabetes (T1D) during the follow-up. Fecal and blood samples were collected from 26 children tested positive for at least one diabetes-associated autoantibody (IAA, GADA, IA-2A, or ICA) and matched autoantibody-negative children with HLA-conferred susceptibility to T1D. Case-control pairs were matched for HLA-DQB1 haplotype, age, gender, and early childhood nutrition. Bacterial 16S and fungal ITS2 sequencing and analyses of the markers of intestinal inflammation, namely HBD2, calprotectin, and secretory total IgA, were performed using fecal samples. Blood samples were analyzed for the levels of ASCA IgA/IgG and circulating cytokines IFNG, IL-17, and IL-22. After the analyses, the children were followed for development of clinical T1D (median 8 years and 8 months). During the follow-up nine autoantibody-positive children were diagnosed with T1D, whereas none of the autoantibody-negative children developed T1D.
Figure 2
Figure 2
Fungal community characteristics in children with or without T1D-associated autoantibodies. (A) Relative abundance of fungal phyla Ascomycota (left columns) and Basidiomycota (right columns). Children without autoantibodies: black columns and children with autoantibodies: gray columns. (B) Relative abundance of 20 most abundant fungal genera in children with (gray bars) and without autoantibodies (black bars). (C–E) The relative abundances of Debaryomyces(C), Malessezia(D), and Verticillium(E) in healthy children without autoantibodies, in children with a different number of autoantibodies and in children who have progressed from autoantibody-positive state to clinical T1D. (F,G) Number of OTUs and Shannon diversity index in healthy children without autoantibodies, in children with a different number of autoantibodies and in children who have progressed from autoantibody-positive state to clinical T1D. Healthy children without autoantibodies are marked with open circles, children with 1–4 autoantibodies with black circles and children who have progressed to clinical disease with red circle. p-values were calculated with the Mann–Whitney U-test. *p < 0.05, **p < 0.01.
Figure 3
Figure 3
Hierarchical clustering over bacterial and fungal taxa and PCoA plots of fungal and bacterial communities. (A) Heatmap showing the clustering of the relative abundances. The clustering resulted in three major clusters (Clusters 1, 4, and 5) defined by differential abundance of fungi belonging to the phylum Ascomycota and the bacterial phyla Firmicutes and Bacteroidetes. Clusters 1, 4, and 5 are encircled with black borders. In the heatmap children with autoantibodies are denoted with AAb+ (red font) and autoantibody-negative children with AAb (blue font). Children who have progressed from autoantibody-positive state to clinical disease are denoted with T1D and a red circle in the heatmap. Color intensity of the heatmap increases with the taxa relative abundance from low (blue) to high (red). (B,C) Principal coordinate analysis (PCoA) biplots (incorporate taxonomy information) on weighted UniFrac distances between the fungal (B) and bacterial (C) gut microbial communities profiles of children at risk of the type 1 diabetes development. Each point represent a single sample and is colored according to the major taxa clusters (Clusters 1, 4, 5, and other), as defined by the hierarchical clustering analysis. Order and genus-level taxonomy displayed by biplot arrows illustrates that the abundance of (B) the Saccharomyces and Candida contribute to the separation of Cluster 1 and Cluster 4, and (C) Clostridiales and Bacteroidales contribute to the distinct clustering patterns of Cluster 1 in comparison to Clusters 4 and 5. p-values were calculated with the Mann–Whitney U-test. *p < 0.05, **p < 0.01. Grouping significance was determined using the PERMANOVA (999 permutations) with the adonis function in the vegan R package (p < 0.001).
Figure 4
Figure 4
Inflammatory markers in different clusters and in children with or without beta-cell autoimmunity. (A) Fecal concentrations of HBD2 in the Clusters 1, 4, and 5. HBD2 levels were higher in the species Cluster 4 compared to Clusters 1 and 5. (B) Children with autoantibodies had elevated levels of fecal HBD2 compared to autoantibody-negative children. (C) Children with only one autoantibody had elevated levels of fecal HBD2 compared to autoantibody-negative children. (D) Serum ASCA IgG concentrations were significantly higher in the Clusters 1 and 4 compared to the Cluster 5. (E) Serum ASCA IgG concentrations in AAb- and in AAb+ children. (F) The autoantibody-positive children who have progressed to clinical disease had elevated serum ASCA IgG antibodies compared to autoantibody-negative children. (G) The relationship between serum ASCA IgA levels and seropositivity duration in the species Cluster 4. (H) The relationship between fecal total IgA and relative abundance of Saccharomycetes in the Cluster 4. (I) The relationship between fecal total IgA and relative abundance of Saccharomyces in the Cluster 4. Healthy children without autoantibodies are marked with open circles, children with 1–4 autoantibodies with black circles and children who have progressed to clinical disease with red circle. Horizontal lines represent median values. p-values were calculated with the Mann–Whitney U-test. Correlations were calculated with the Spearman rank correlation test.*p < 0.05, **p < 0.01.
Figure 5
Figure 5
Serum cytokine concentration in different clusters. (A,B) The relationships between serum IFNG and relative abundance of fecal Bacteroidetes and Firmicutes in the Cluster 1. (D,E) The relationships between serum IL-17A and relative abundance of fecal Bacteroidetes and Firmicutes in the Cluster 1. (C,F) IFNG and IL-17A levels were significantly higher in the Cluster 5 compared to the Clusters 1 and 4. (G,H) The relationships between serum IFNG and relative abundance of fecal Bacteroidetes and Firmicutes in the Cluster 1. Horizontal lines represent median values. p-values were calculated with the Mann–Whitney U-test. Correlations were calculated with the Spearman rank correlation test.*p < 0.05, **p < 0.01.

References

    1. Bendelac A, Carnaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med. (1987) 166:823–32. 10.1084/jem.166.4.823
    1. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet. (1974) 2:1279–83. 10.1016/S0140-6736(74)90140-8
    1. MacCuish AC, Irvine WJ, Barnes EW, Duncan LJ. Antibodies to pancreatic islet cells in insulin-dependent diabetics with coexistent autoimmune disease. Lancet. (1974) 2:1529–31. 10.1016/S0140-6736(74)90281-5
    1. Morgan NG, Leete P, Foulis AK, Richardson SJ. Islet inflammation in human type 1 diabetes mellitus. IUBMB Life. (2014) 66:723–34. 10.1002/iub.1330
    1. Ferreira RC, Guo H, Coulson RM, Smyth DJ, Pekalski ML, Burren OS, et al. . A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. Diabetes. (2014) 63:2538–50. 10.2337/db13-1777
    1. Honkanen J, Nieminen JK, Gao R, Luopajarvi K, Salo HM, Ilonen J, et al. . IL-17 immunity in human type 1 diabetes. J Immunol. (2010) 185:1959–67. 10.4049/jimmunol.1000788
    1. Kallionpaa H, Elo LL, Laajala E, Mykkanen J, Ricano-Ponce I, Vaarma M, et al. . Innate immune activity is detected prior to seroconversion in children with HLA-conferred type 1 diabetes susceptibility. Diabetes. (2014) 63:2402–14. 10.2337/db13-1775
    1. Marwaha AK, Crome SQ, Panagiotopoulos C, Berg KB, Qin H, Ouyang Q, et al. . Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol. (2010) 185:3814–8. 10.4049/jimmunol.1001860
    1. Reinert-Hartwall L, Honkanen J, Salo HM, Nieminen JK, Luopajarvi K, Harkonen T, et al. . Th1/Th17 plasticity is a marker of advanced beta cell autoimmunity and impaired glucose tolerance in humans. J Immunol. (2015) 194:68–75. 10.4049/jimmunol.1401653
    1. de Goffau MC, Luopajarvi K, Knip M, Ilonen J, Ruohtula T, Harkonen T, et al. . Fecal microbiota composition differs between children with beta-cell autoimmunity and those without. Diabetes. (2013) 62:1238–44. 10.2337/db12-0526
    1. Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G, et al. . Toward defining the autoimmune microbiome for type 1 diabetes. ISME J. (2011) 5:82–91. 10.1038/ismej.2010.92
    1. Kostic AD, Gevers D, Siljander H, Vatanen T, Hyotylainen T, Hamalainen AM, et al. . The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe. (2015) 17:260–73. 10.1016/j.chom.2015.01.001
    1. Vatanen T, Franzosa EA, Schwager R, Tripathi S, Arthur TD, Vehik K, et al. . The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature. (2018) 562:589–94. 10.1038/s41586-018-0620-2
    1. Vatanen T, Kostic AD, d'Hennezel E, Siljander H, Franzosa EA, Yassour M, et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell. (2016) 165:842–53. 10.1016/j.cell.2016.04.007
    1. Westerholm-Ormio M, Vaarala O, Pihkala P, Ilonen J, Savilahti E. Immunologic activity in the small intestinal mucosa of pediatric patients with type 1 diabetes. Diabetes. (2003) 52:2287–95. 10.2337/diabetes.52.9.2287
    1. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al. . Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature. (2008) 455:1109–13. 10.1038/nature07336
    1. Hallen-Adams HE, Suhr MJ. Fungi in the healthy human gastrointestinal tract. Virulence. (2017) 8:352–8. 10.1080/21505594.2016.1247140
    1. Richard ML, Sokol H. The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. (2019) 16:331–45. 10.1038/s41575-019-0121-2
    1. Ferreira R, Limeta A, Nielsen J. Tackling cancer with yeast-based technologies. Trends Biotechnol. (2018). 10.1016/j.tibtech.2018.11.013
    1. Fujimura KE, Sitarik AR, Havstad S, Lin DL, Levan S, Fadrosh D, et al. . Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. Nat Med. (2016) 22:1187–91. 10.1038/nm.4176
    1. Hoarau G, Mukherjee PK, Gower-Rousseau C, Hager C, Chandra J, Retuerto MA, et al. . Bacteriome and mycobiome interactions underscore microbial dysbiosis in familial Crohn's disease. MBio. (2016) 7:e01250–16. 10.1128/mBio.01250-16
    1. Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, et al. . Fungal microbiota dysbiosis in IBD. Gut. (2017) 66:1039–48. 10.1136/gutjnl-2015-310746
    1. Iliev ID, Leonardi I. Fungal dysbiosis: immunity and interactions at mucosal barriers. Nat Rev Immunol. (2017) 17:635–46. 10.1038/nri.2017.55
    1. Knip M, Virtanen SM, Akerblom HK. Infant feeding and the risk of type 1 diabetes. Am J Clin Nutr. (2010) 91:1506S−13S. 10.3945/ajcn.2010.28701C
    1. Sjoroos M, Iitia A, Ilonen J, Reijonen H, Lovgren T. Triple-label hybridization assay for type-1 diabetes-related HLA alleles. Biotechniques. (1995) 18:870–7.
    1. Vaarala O, Ilonen J, Ruohtula T, Pesola J, Virtanen SM, Harkonen T, et al. . Removal of bovine insulin from cow's milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study. Arch Pediatr Adolesc Med. (2012) 166:608–14. 10.1001/archpediatrics.2011.1559
    1. Ihrmark K, Bodeker IT, Cruz-Martinez K, Friberg H, Kubartova A, Schenck J, et al. . New primers to amplify the fungal ITS2 region—evaluation by 454-sequencing of artificial and natural communities. FEMS Microbiol Ecol. (2012) 82:666–77. 10.1111/j.1574-6941.2012.01437.x
    1. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. . QIIME allows analysis of high-throughput community sequencing data. Nat Methods. (2010) 7:335–6. 10.1038/nmeth.f.303
    1. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics. (2011) 27:2194–200. 10.1093/bioinformatics/btr381
    1. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. (2010) 26:2460–1. 10.1093/bioinformatics/btq461
    1. McDonald D, Price MN, Goodrich J, Nawrocki EP, deSantis TZ, Probst A, et al. . An improved greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. (2012) 6:610–8. 10.1038/ismej.2011.139
    1. Nilsson RH, Larsson KH, Taylor AFS, Bengtsson-Palme J, Jeppesen TS, Schigel D, et al. . The UNITE database for molecular identification of fungi: handling dark taxa and parallel taxonomic classifications. Nucleic Acids Res. (2019) 47:D259–64. 10.1093/nar/gky1022
    1. Weiss S, Xu ZZ, Peddada S, Amir A, Bittinger K, Gonzalez A, et al. . Normalization and microbial differential abundance strategies depend upon data characteristics. Microbiome. (2017) 5:27. 10.1186/s40168-017-0237-y
    1. Lozupone CA, Hamady M, Kelley ST, Knight R. Quantitative and qualitative beta diversity measures lead to different insights into factors that structure microbial communities. Appl Environ Microbiol. (2007) 73:1576–85. 10.1128/AEM.01996-06
    1. Vazquez-Baeza Y, Pirrung M, Gonzalez A, Knight R. EMPeror: a tool for visualizing high-throughput microbial community data. Gigascience. (2013) 2:16. 10.1186/2047-217X-2-16
    1. Lehtonen OP, Grahn EM, Stahlberg TH, Laitinen LA. Amount and avidity of salivary and serum antibodies against Streptococcus mutans in two groups of human subjects with different dental caries susceptibility. Infect Immun. (1984) 43:308–13. 10.1128/IAI.43.1.308-313.1984
    1. Oksanen J, Blanchet FG, Kindt R, Legendre P, Minchin PR, O'Hara B, et al. Vegan: Community Ecology Package (2016). Available online at:
    1. Hoffmann C, Dollive S, Grunberg S, Chen J, Li H, Wu GD, et al. . Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS ONE. (2013) 8:e66019. 10.1371/journal.pone.0066019
    1. Motooka D, Fujimoto K, Tanaka R, Yaguchi T, Gotoh K, Maeda Y, et al. . Fungal ITS1 deep-sequencing strategies to reconstruct the composition of a 26-species community and evaluation of the gut mycobiota of healthy japanese individuals. Front Microbiol. (2017) 8:238. 10.3389/fmicb.2017.00238
    1. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. . Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. (2006) 203:2271–9. 10.1084/jem.20061308
    1. Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, et al. . Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. (2005) 54:1232–6. 10.1136/gut.2004.060228
    1. Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, et al. . A microbial signature for Crohn's disease. Gut. (2017) 66:813–22. 10.1136/gutjnl-2016-313235
    1. Romani L. Immunity to fungal infections. Nat Rev Immunol. (2004) 4:1–23. 10.1038/nri1255
    1. Kallmann BA, Huther M, Tubes M, Feldkamp J, Bertrams J, Gries FA, et al. . Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes. (1997) 46:237–43. 10.2337/diabetes.46.2.237
    1. Kuitunen M, Saukkonen T, Ilonen J, Akerblom HK, Savilahti E. Intestinal permeability to mannitol and lactulose in children with type 1 diabetes with the HLA-DQB1*02 allele. Autoimmunity. (2002) 35:365–8. 10.1080/0891693021000008526
    1. Tiittanen M, Westerholm-Ormio M, Verkasalo M, Savilahti E, Vaarala O. Infiltration of forkhead box P3-expressing cells in small intestinal mucosa in coeliac disease but not in type 1 diabetes. Clin Exp Immunol. (2008) 152:498–507. 10.1111/j.1365-2249.2008.03662.x
    1. Vaarala O, Atkinson MA, Neu J. The perfect storm for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes. (2008) 57:2555–62. 10.2337/db08-0331
    1. Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigaluppi E, et al. . Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia. (2006) 49:2824–7. 10.1007/s00125-006-0465-3
    1. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al. . Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. (2013) 309:2473–9. 10.1001/jama.2013.6285
    1. Kolho KL, Sipponen T, Valtonen E, Savilahti E. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis. (2014) 29:43–50. 10.1007/s00384-013-1775-9
    1. Hamad I, Sokhna C, Raoult D, Bittar F. Molecular detection of eukaryotes in a single human stool sample from senegal. PLoS ONE. (2012) 7:e40888. 10.1371/journal.pone.0040888
    1. Scanlan PD, Marchesi JR. Micro-eukaryotic diversity of the human distal gut microbiota: qualitative assessment using culture-dependent and -independent analysis of faeces. ISME J. (2008) 2:1183–93. 10.1038/ismej.2008.76
    1. de Luca A, Zelante T, D'Angelo C, Zagarella S, Fallarino F, Spreca A, et al. . IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol. (2010) 3:361–73. 10.1038/mi.2010.22
    1. Kinnebrew MA, Buffie CG, Diehl GE, Zenewicz LA, Leiner I, Hohl TM, et al. . Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity. (2012) 36:276–87. 10.1016/j.immuni.2011.12.011
    1. Schauber J, Svanholm C, Termen S, Iffland K, Menzel T, Scheppach W, et al. . Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. Gut. (2003) 52:735–41. 10.1136/gut.52.5.735
    1. Fan D, Coughlin LA, Neubauer MM, Kim J, Kim MS, Zhan X, et al. . Activation of HIF-1α and LL-37 by commensal bacteria inhibits Candida albicans colonization. Nat Med. (2015) 21:808–14. 10.1038/nm.3871
    1. Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol. (2010) 10:159–69. 10.1038/nri2710
    1. Otte JM, Zdebik AE, Brand S, Chromik AM, Strauss S, Schmitz F, et al. . Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. Regul Pept. (2009) 156:104–17. 10.1016/j.regpep.2009.03.009
    1. Vaarala O. Human intestinal microbiota and type 1 diabetes. Curr Diab Rep. (2013) 13:601–7. 10.1007/s11892-013-0409-5
    1. Bacher P, Hohnstein T, Beerbaum E, Rocker M, Blango MG, Kaufmann S, et al. . Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans. Cell. (2019) 176:1340–55.e15. 10.1016/j.cell.2019.01.041
    1. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, et al. . Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature. (2012) 484:514–8. 10.1038/nature10957
    1. Erb Downward JR, Falkowski NR, Mason KL, Muraglia R, Huffnagle GB. Modulation of post-antibiotic bacterial community reassembly and host response by Candida albicans. Sci Rep. (2013) 3:2191. 10.1038/srep02191
    1. Yu L, Zhao XK, Cheng ML, Yang GZ, Wang B, Liu HJ, et al. . Saccharomyces boulardii administration changes gut microbiota and attenuates D-Galactosamine-induced liver injury. Sci Rep. (2017) 7:1359. 10.1038/s41598-017-01271-9
    1. Sovran B, Planchais J, Jegou S, Straube M, Lamas B, Natividad JM, et al. . Enterobacteriaceae are essential for the modulation of colitis severity by fungi. Microbiome. (2018) 6:152. 10.1186/s40168-018-0538-9

Source: PubMed

3
Abonneren